Literature DB >> 26036142

YAP in MAPK pathway targeted therapy resistance.

Keith T Flaherty1, Jennifer A Wargo, Trever G Bivona.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26036142      PMCID： PMC4612653          DOI： 10.1080/15384101.2015.1032644

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors:  Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

2.  Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research.

Authors:  Charles L Sawyers; Laura J van 't Veer
Journal:  Clin Cancer Res       Date:  2014-09-09       Impact factor: 12.531

Review 3.  Major therapeutic developments and current challenges in advanced melanoma.

Authors:  R J Sullivan; K T Flaherty
Journal:  Br J Dermatol       Date:  2014-01       Impact factor: 9.302

Review 4.  The emerging roles of YAP and TAZ in cancer.

Authors:  Toshiro Moroishi; Carsten Gram Hansen; Kun-Liang Guan
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

5.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Authors:  Luping Lin; Saurabh Asthana; Elton Chan; Sourav Bandyopadhyay; Maria M Martins; Victor Olivas; Jenny Jiacheng Yan; Luu Pham; Mingxue Michelle Wang; Gideon Bollag; David B Solit; Eric A Collisson; Charles M Rudin; Barry S Taylor; Trever G Bivona
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 6.  Genetics and biomarkers in personalisation of lung cancer treatment.

Authors:  Rafael Rosell; Trever G Bivona; Niki Karachaliou
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321

7.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962
  7 in total
  6 in total

1.  RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.

Authors:  M Lee Schmidt; Katharine R Hobbing; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

Review 2.  A New View of Pathway-Driven Drug Resistance in Tumor Proliferation.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Trends Pharmacol Sci       Date:  2017-02-27       Impact factor: 14.819

3.  EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.

Authors:  Susanne Scheipl; Michelle Barnard; Lucia Cottone; Mette Jorgensen; David H Drewry; William J Zuercher; Fabrice Turlais; Hongtao Ye; Ana P Leite; James A Smith; Andreas Leithner; Peter Möller; Silke Brüderlein; Naomi Guppy; Fernanda Amary; Roberto Tirabosco; Sandra J Strauss; Nischalan Pillay; Adrienne M Flanagan
Journal:  J Pathol       Date:  2016-05-31       Impact factor: 7.996

4.  Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.

Authors:  Ke Gong; Gao Guo; Nicole A Beckley; Xiaoyao Yang; Yue Zhang; David E Gerber; John D Minna; Sandeep Burma; Dawen Zhao; Esra A Akbay; Amyn A Habib
Journal:  Nat Commun       Date:  2021-12-01       Impact factor: 14.919

5.  Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors.

Authors:  Meng Su; Lei Zhan; Yong Zhang; Jingdong Zhang
Journal:  J Gastrointest Oncol       Date:  2021-06

6.  Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.

Authors:  Shumei Song; Yuan Li; Yan Xu; Lang Ma; Melissa Pool Pizzi; Jiankang Jin; Ailing W Scott; Longfei Huo; Ying Wang; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Namita D Shanbhag; Randy L Johnson; Jaffer A Ajani
Journal:  Mol Oncol       Date:  2020-04-07       Impact factor: 6.603
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.